Data from the yellow card scheme for reporting adverse events to the Medicines and Healthcare Products Regulatory Agency (MHRA) show that up to 31 January 2025 there were 22 deaths from adverse reactions associated with use of GLP-1 agonists for weight loss and 60 linked to use for treating type 2 diabetes.
reify•7mo ago
10 deaths too many, thats not including the 82 from February
even worse back in February 82 deaths.
British medical jounal
BMJ 2025; 388 doi: https://doi.org/10.1136/bmj.r390 (Published 25 February 2025)
GLP-1 agonists: 82 deaths linked to adverse reactions, UK data show
https://www.bmj.com/content/388/bmj.r390
Data from the yellow card scheme for reporting adverse events to the Medicines and Healthcare Products Regulatory Agency (MHRA) show that up to 31 January 2025 there were 22 deaths from adverse reactions associated with use of GLP-1 agonists for weight loss and 60 linked to use for treating type 2 diabetes.